02 / IT · Analysis
BioMap launches an AI for nonclinical drug safety assessment
The system adds toxicity prediction to nonclinical research and retains animal studies for model validation.
BioMap announced the launch of an AI system for nonclinical drug safety assessment, Pandaily reported on 20 Nov.
According to Pandaily, BioMap added toxicity prediction to its nonclinical research workflow.
In the workflow Pandaily described, researchers use toxicity predictions to assess drug safety and animal studies to check the model behind those predictions.
Toxicity prediction in nonclinical research
Pandaily identified xTrimoTox as the model that predicts toxicity.
The report put its use in nonclinical drug safety assessment, where researchers assess potential harms outside human trials.
Animal studies in model validation
Pandaily reported that BioMap retained animal studies in its model validation process.
Those studies serve to validate xTrimoTox, the model that supplies toxicity predictions to the research workflow, according to the report.